<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="for autoimmunity and act as receptors for microbes, like the" exact="influenza" post="viruses, and toxins, such as the cholera toxin. The"/>
 <result pre="autoimmune etiology of the disease. Keywords ganglioside Guillain-Barre syndrome complement" exact="narcolepsy" post="sialic acid Subject terms Diagnostic markers Autoimmunity Prognostic markers"/>
 <result pre="different cells and structures to cause autoimmune diseases. These include" exact="multiple sclerosis," post="narcolepsy, optic neuritis, limbic encephalitis, and Guillain–Barré syndrome. Immunoinflammatory"/>
 <result pre="structures to cause autoimmune diseases. These include multiple sclerosis, narcolepsy," exact="optic neuritis," post="limbic encephalitis, and Guillain–Barré syndrome. Immunoinflammatory mechanisms are believed"/>
 <result pre="mechanisms are believed to be involved in various forms of" exact="dementia" post="and neurodegenerative diseases, as well. Our understanding of many"/>
 <result pre="autoimmunity are being better recognized, but in some diseases, like" exact="multiple sclerosis" post="(MS) and narcolepsy, uncertainty about the real targets still"/>
 <result pre="In recent years, gangliosides received renewed interest as targets for" exact="cancer" post="immunotherapy. It is known that the GD3 ganglioside is"/>
 <result pre="them.17 Sialic acids are also exploited by viruses like the" exact="influenza" post="viruses, to be internalized into the host cells through"/>
 <result pre="viruses, bacteria and parasites, like blood merozoites of the deadliest" exact="malaria" post="parasite Plasmodium falciparum, have learnt to exploit sialic acids/gangliosides"/>
 <result pre="also occur primarily in humans. Another special example is the" exact="influenza" post="virus. Influenza viruses bind to sialic acids via their"/>
 <result pre="viruses to the cell. Of great importance, different types of" exact="influenza" post="viruses carry H proteins with different sialic acid specificities."/>
 <result pre="H proteins with different sialic acid specificities. Thus, only certain" exact="influenza" post="viruses (H1, H2, H3) are infecting humans, while H1"/>
 <result pre="infect birds. The H5 and H7 types are particularly dangerous" exact="influenza" post="virus types for birds and a potential risk for"/>
 <result pre="Variation in the H and N protein structures in pandemic" exact="influenza" post="strains forces the adoption of new vaccines against the"/>
 <result pre="H and N proteins for seasonally occurring new types of" exact="influenza" post="virus during epidemics. Another major immunological function of gangliosides"/>
 <result pre="A deficiency in the anchoring mechanism causes a hematological disorder," exact="paroxysmal nocturnal hemoglobinuria" post="(PNH), where affected blood cells become the target for"/>
 <result pre="in the anchoring mechanism causes a hematological disorder, paroxysmal nocturnal" exact="hemoglobinuria" post="(PNH), where affected blood cells become the target for"/>
 <result pre="were identified as the cause of an autosomal recessive infantile-onset" exact="epilepsy" post="syndrome.47 In addition, mutations in ST3GAL5, which codes for"/>
 <result pre="for another enzyme of the ganglioside biosynthetic pathways, result in" exact="hereditary spastic paraplegia" post="and intellectual deficits.10 In addition to gangliosidoses, ganglioside accumulation"/>
 <result pre="enzyme of the ganglioside biosynthetic pathways, result in hereditary spastic" exact="paraplegia" post="and intellectual deficits.10 In addition to gangliosidoses, ganglioside accumulation"/>
 <result pre="Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) and" exact="multiple sclerosis" post="(MS) may involve disturbed ganglioside metabolism.48 On the other"/>
 <result pre="may involve disturbed ganglioside metabolism.48 On the other hand, the" exact="peripheral neuropathy" post="Guillain–Barré syndrome (GBS) is an example of a disease"/>
 <result pre="involve disturbed ganglioside metabolism.48 On the other hand, the peripheral" exact="neuropathy" post="Guillain–Barré syndrome (GBS) is an example of a disease"/>
 <result pre="as a possible treatment strategy57. The presence of AGA in" exact="amyotrophic lateral sclerosis" post="(ALS) has been investigated, but recent studies found no"/>
 <result pre="healthy controls.58 AGA were also sporadically identified in cases of" exact="myasthenia gravis" post="and Lambert–Eaton syndrome59,60 and in a single case of"/>
 <result pre="could contribute to axonal damage.62,65 AGAs have been found in" exact="systemic lupus erythematosus" post="(SLE) patients with neuropsychiatric manifestations of the disease. In"/>
 <result pre="contribute to axonal damage.62,65 AGAs have been found in systemic" exact="lupus erythematosus" post="(SLE) patients with neuropsychiatric manifestations of the disease. In"/>
 <result pre="(CD), which can have a variety of neurological manifestations, e.g" exact="cerebellar ataxia," post="peripheral neuropathy, epilepsy and depression68,69, has been associated with"/>
 <result pre="can have a variety of neurological manifestations, e.g cerebellar ataxia," exact="peripheral neuropathy," post="epilepsy and depression68,69, has been associated with anti-GM1 antibodies.70"/>
 <result pre="a variety of neurological manifestations, e.g cerebellar ataxia, peripheral neuropathy," exact="epilepsy" post="and depression68,69, has been associated with anti-GM1 antibodies.70 The"/>
 <result pre="type 1 diabetes but their correlation with the development of" exact="diabetic neuropathy" post="has not been confirmed.73,74 AGAs in healthy individuals The"/>
 <result pre="1 diabetes but their correlation with the development of diabetic" exact="neuropathy" post="has not been confirmed.73,74 AGAs in healthy individuals The"/>
 <result pre="but the most relevant ones are an acute inflammatory demyelinating" exact="polyneuropathy" post="(AIDP), the axonal forms (AMAN and AMSAN), Miller–Fisher syndrome"/>
 <result pre="forms (AMAN and AMSAN), Miller–Fisher syndrome (MFS) and Bickerstaff brainstem" exact="encephalitis" post="(BEE). AIDP is the most common form of GBS."/>
 <result pre="main axonal forms of GBS are recognized: acute motor axonal" exact="neuropathy" post="(AMAN) and acute motor and sensory axonal neuropathy (AMSAN)."/>
 <result pre="motor axonal neuropathy (AMAN) and acute motor and sensory axonal" exact="neuropathy" post="(AMSAN). According to Hughes and Cornblath, antibodies to GM1,"/>
 <result pre="and GalNac-GD1a are in particular implicated in acute motor axonal" exact="neuropathy" post="and also, with the exception of GalNac-GD1a, in acute"/>
 <result pre="the clinical triad of ophthalmoplegia, ataxia and areflexia. Bickerstaff brainstem" exact="encephalitis" post="(BEE), clinically very similar to MFS, is characterized by"/>
 <result pre="Polynesia. It has been associated with neurological sequelae such as" exact="microcephaly" post="in newborns and GBS in adults.115,116 Microcephaly seems to"/>
 <result pre="have been associated with GBS, like dengue, West Nile and" exact="chikungunya" post="with sporadic reports in the literature. Case reports have"/>
 <result pre="Case reports have been published on GBS in patients with" exact="hepatitis" post="E121 or herpes simplex virus infection.122 Parvovirus B19 infections"/>
 <result pre="been published on GBS in patients with hepatitis E121 or" exact="herpes simplex" post="virus infection.122 Parvovirus B19 infections are associated with a"/>
 <result pre="a 23-year-old immunocompetent woman with a PB19 infection associated with" exact="hemolytic anemia" post="and cranial polyneuropathy.123 While in some cases the associations"/>
 <result pre="23-year-old immunocompetent woman with a PB19 infection associated with hemolytic" exact="anemia" post="and cranial polyneuropathy.123 While in some cases the associations"/>
 <result pre="AGAs may be key players of the neurological damage.127,128 Secondary" exact="narcolepsy" post="following Pandemrix® vaccination Type I narcolepsy (NT1) is a"/>
 <result pre="the neurological damage.127,128 Secondary narcolepsy following Pandemrix® vaccination Type I" exact="narcolepsy" post="(NT1) is a chronic sleep disorder characterized by excessive"/>
 <result pre="following Pandemrix® vaccination Type I narcolepsy (NT1) is a chronic" exact="sleep disorder" post="characterized by excessive daytime sleepiness, cataplexy and, commonly, parasomnias.129,130"/>
 <result pre="excessive daytime sleepiness, cataplexy and, commonly, parasomnias.129,130 The prevalence of" exact="narcolepsy" post="is circa 30 per 100,000. It occurs in a"/>
 <result pre="by a strong emotional response. It is essentially unique to" exact="narcolepsy" post="type I.132 A clue to the etiology of narcolepsy"/>
 <result pre="to narcolepsy type I.132 A clue to the etiology of" exact="narcolepsy" post="was obtained, when narcoleptic dogs were found to be"/>
 <result pre="investigation, but in the majority of cases it is an" exact="autoimmune disease." post="No direct evidence is available for the pathogenetic mechanisms"/>
 <result pre="killing of orexinergic neurons to give a narcolepsy-like phenotype.135 Surprisingly," exact="narcolepsy" post="has been associated with the pandemic H1N1 flu vaccine."/>
 <result pre="in other countries, after the vaccination campaign against the H1N1-type" exact="influenza" post="A with the Pandemrix vaccine (GSK), a clear increase"/>
 <result pre="A with the Pandemrix vaccine (GSK), a clear increase in" exact="narcolepsy" post="cases was reported. The cases were observed in particular"/>
 <result pre="years of age. The vaccination increased the risk of developing" exact="narcolepsy" post="6.5–14.4-fold in vaccinated subjects compared to unvaccinated ones.136–138 An"/>
 <result pre="in vaccinated subjects compared to unvaccinated ones.136–138 An increase in" exact="narcolepsy" post="was not restricted to the flu vaccine. Interestingly, in"/>
 <result pre="absence of vaccination, a 6-fold increase in the incidence of" exact="narcolepsy" post="was observed after the 2009 influenza pandemics.139 The mechanisms"/>
 <result pre="in the incidence of narcolepsy was observed after the 2009" exact="influenza" post="pandemics.139 The mechanisms and potential autoantigen underlying the development"/>
 <result pre="autoantigen underlying the development of H1N1 vaccine- or virus infection-induced" exact="narcolepsy" post="have remained elusive. The receptor for the H1N1-virus hemagglutinin"/>
 <result pre="potentially favor cross-reactive antigen presentation by MHC class II.142 Another" exact="influenza" post="A (H1N1) vaccine, Arepanrix (also by GSK) with a"/>
 <result pre="and antigenicity as Pandemrix,143 did not show any increase in" exact="narcolepsy" post="incidence.144 This could have been due to a different"/>
 <result pre="anti-GM4, in the sera of 18.1% of patients with Pandemrix-induced" exact="narcolepsy" post="(compared to 7.3% in unvaccinated controls). The origin of"/>
 <result pre="2). Fig. 2 A model for the pathogenesis of secondary" exact="narcolepsy" post="following Pandemrix® vaccination. In susceptible recipients, i.e., in those,"/>
 <result pre="targeted attack against hypothalamic orexinergic neurons and to the subsequent" exact="narcolepsy" post="onset. Antiganglioside antibodies could emerge upon complex formation between"/>
 <result pre="debated) Chapman50, Hatziflippu52, Koutsouraki51 Multiple sclerosis GM3, GQ1b Pender65 Systemic" exact="lupus erythematosus" post="GM1 Costellat152, Galeazzi67 Celiac disease GM1 (or GM1-gliadin complexes)"/>
 <result pre="Type I diabetes GM1, GM2, GM3, GD1b, GD1a Lucchetta73 Secondary" exact="narcolepsy" post="GM3, GM4 Saariaho137 Guillain–Barré syndrome AIDP: GT1b AMAN: GM1,"/>
 <result pre="GD1a MF: GQ1b BE: GQ1b Hughes and Cornblath88, Naik85 Breast" exact="cancer" post="GM3, GD3, 9-O-Ac GD3, 9-O-Ac GT3 Groux-Degroote154 Conclusions Gangliosides"/>
 <result pre="parisiennePathol. Biol.20055353653810.1016/j.patbio.2005.06.00616084033 9.TamCCet al.Guillain-Barrè syndrome and preceding infection with Campylobacter," exact="influenza" post="and Epstein-Barr virus in the general practice research databasePLoS"/>
 <result pre="22.OhmiYet al.Gangliosides are essential in the protection of inflammation and" exact="neurodegeneration" post="via maintenance of lipid rafts: elucidation by a series"/>
 <result pre="33.SimonsKIkonenEFunctional rafts in cell membranesNature199738756957210.1038/424089177342 34.PikeLJLipid raftsJ. Lipid Res.20034465566710.1194/jlr.R200021-JLR20012562849 35.HampsonAWMackenzieJSThe" exact="influenza" post="virusesMed. J. Aust.2006185S39S4310.5694/j.1326-5377.2006.tb00705.x17115950 36.Meri, S. Self-nonself discrimination by the"/>
 <result pre="lysis by binding of GPI-anchored protectin (CD59)Gastroenterology200112047047910.1053/gast.2001.2119711159887 47.SimpsonMAet al.Infantile-onset symptomatic" exact="epilepsy" post="syndrome caused by a homozygous loss-of-function mutation of GM3"/>
 <result pre="Ann. N.Y. Acad. Sci.845, 363–373 (1998). 58.KolleweKet al.Anti-ganglioside antibodies in" exact="amyotrophic lateral sclerosis" post="revisitedPLoS ONE20151011110.1371/journal.pone.0125339 59.ScaioliVAndreettaFMantegazzaRUnusual neurophysiological and immunological findings in myasthenia"/>
 <result pre="myasthenia gravis: a case reportJ. Peripher. Nerv. Syst.20049929710.1111/j.1085-9489.2004.09207.x15104696 60.MitsuiYet al.Sensorimotor" exact="polyneuropathy" post="associated with chronic lymphocytic leukemia, IgM antigangliosides antibody and"/>
 <result pre="case reportJ. Peripher. Nerv. Syst.20049929710.1111/j.1085-9489.2004.09207.x15104696 60.MitsuiYet al.Sensorimotor polyneuropathy associated with" exact="chronic lymphocytic leukemia," post="IgM antigangliosides antibody and human T-cell leukemia virus I"/>
 <result pre="with chronic lymphocytic leukemia, IgM antigangliosides antibody and human T-cell" exact="leukemia" post="virus I infectionMuscle Nerve1999221461146510.1002/(SICI)1097-4598(199910)22:10&amp;lt;1461::AID-MUS19&amp;gt;3.0.CO;2-T10487916 61.FavoniVLiguoriRIncensiAFilecciaEDonadioVThe incidental finding of elevated"/>
 <result pre="of sphthalmoplegia, Ataxia and areflexia)N. Engl. J. Med.1956255576510.1056/NEJM19560712255020113334797 91.ShahrizailaNYukiNBickerstaff brainstem" exact="encephalitis" post="and Fisher syndrome: anti-GQ1b antibody syndromeJ. Neurol. Neurosurg. Psychiatry20138457658310.1136/jnnp-2012-30282422984203"/>
 <result pre="syndrome: a case-control studyNeurology1998511110111510.1212/WNL.51.4.11109781538 102.RhoYIlOverlapping Guillain-Barré syndrome and Bickerstaff’s brainstem" exact="encephalitis" post="associated with Epstein Barr virusKorean J. Pediatr.20145745710.3345/kjp.2014.57.10.45725379047 103.RodríguezYet al.Guillain–Barré"/>
 <result pre="with Epstein Barr virusKorean J. Pediatr.20145745710.3345/kjp.2014.57.10.45725379047 103.RodríguezYet al.Guillain–Barré syndrome, transverse" exact="myelitis" post="and infectious diseasesCell. Mol. Immunol.20181554756210.1038/cmi.2017.14229375121 104.de GrootRCAMeyer SauteurPMUngerWWJvan RossumAMCThings"/>
 <result pre="age 19–24 months of 19 children who were born with" exact="microcephaly" post="and laboratory evidence of congenital Zika virus infection during"/>
 <result pre="putative role of gangliosidesBMC Med.2016141310.1186/s12916-016-0601-y26728489 118.LuccheseGKanducDZika virus and autoimmunity: from" exact="microcephaly" post="to Guillain-Barré syndrome, and beyondAutoimmun. Rev.20161580180810.1016/j.autrev.2016.03.02027019049 119.NicoDet al.Prevalence of"/>
 <result pre="Neurol. India66, 1324–1331 121.StevensOClaeysKGPoesenKSaegemanVVan DammePDiagnostic challenges and clinical characteristics of" exact="hepatitis" post="e virus-associated guillain-Barré syndromeJAMA Neurol.201774263310.1001/jamaneurol.2016.354127820624 122.MiyajiKet al.Altered gene expression"/>
 <result pre="of glycosyltransferases and sialyltransferases and total amount of glycosphingolipids following" exact="herpes simplex" post="virus infectionCarbohydr. Res.2016434374310.1016/j.carres.2016.08.00427588895 123.Sequeira, J., Calado, A., Dias, M."/>
 <result pre="Dias, M. &amp;amp; Manita, M. Parvovirus B19 infection associated with" exact="hemolytic anemia" post="and cranial polyneuropathy. J. Neurovirol. 10.1007/s13365-017-0562-8 (2017). 124.PlompJJWillisonHJPathophysiological actions"/>
 <result pre="M. &amp;amp; Manita, M. Parvovirus B19 infection associated with hemolytic" exact="anemia" post="and cranial polyneuropathy. J. Neurovirol. 10.1007/s13365-017-0562-8 (2017). 124.PlompJJWillisonHJPathophysiological actions"/>
 <result pre="the etiology, diagnosis and treatment of narcolepsySleep. Med.2001251710.1016/S1389-9457(00)00081-211152978 133.LinLet al.The" exact="sleep disorder" post="canine narcolepsy is caused by a mutation in the"/>
 <result pre="and treatment of narcolepsySleep. Med.2001251710.1016/S1389-9457(00)00081-211152978 133.LinLet al.The sleep disorder canine" exact="narcolepsy" post="is caused by a mutation in the hypocretin (orexin)"/>
 <result pre="associated with an abrupt increase in the incidence of childhood" exact="narcolepsy" post="in FinlandPLoS ONE20127e3353610.1371/journal.pone.003353622470453 137.SaariahoAHet al.Autoantibodies against ganglioside GM3 are"/>
 <result pre="narcolepsy-cataplexy developing after Pandemrix vaccination against 2009 pandemic H1N1 type" exact="influenza" post="virusJ. Autoimmun.201563687510.1016/j.jaut.2015.07.00626227560 138.SturkenboomMCJMThe narcolepsy-pandemic influenza story: can the truth"/>
 <result pre="against 2009 pandemic H1N1 type influenza virusJ. Autoimmun.201563687510.1016/j.jaut.2015.07.00626227560 138.SturkenboomMCJMThe narcolepsy-pandemic" exact="influenza" post="story: can the truth ever be unraveled?Vaccine201533B6B1310.1016/j.vaccine.2015.03.02626022571 139.HanFet al.Narcolepsy"/>
 <result pre="its implication to the development of narcolepsyVaccine2014322980298810.1016/j.vaccine.2014.03.08524721530 142.KimWJet al.Incidence of" exact="narcolepsy" post="before and after MF59-adjuvanted influenza A(H1N1)pdm09 vaccination in South"/>
 <result pre="of narcolepsyVaccine2014322980298810.1016/j.vaccine.2014.03.08524721530 142.KimWJet al.Incidence of narcolepsy before and after MF59-adjuvanted" exact="influenza" post="A(H1N1)pdm09 vaccination in South Korean soldiersVaccine2015334868487210.1016/j.vaccine.2015.07.05526238720 143.CanelleQInnisBLMostRVanDerEvaluation of potential"/>
 <result pre="Pandemrix and Arepanrix, two pH1N1 AS03-adjuvanted vaccines differentially associated with" exact="narcolepsy" post="developmentBrain. Behav. Immun.201547445710.1016/j.bbi.2014.11.00425452148 145.VaaralaOet al.Antigenic differences between AS03 adjuvanted"/>
 <result pre="narcolepsy developmentBrain. Behav. Immun.201547445710.1016/j.bbi.2014.11.00425452148 145.VaaralaOet al.Antigenic differences between AS03 adjuvanted" exact="influenza" post="A (H1N1) pandemic vaccines: Implications for pandemrix-associated narcolepsy riskPLoS"/>
 <result pre="AS03 adjuvanted influenza A (H1N1) pandemic vaccines: Implications for pandemrix-associated" exact="narcolepsy" post="riskPLoS ONE2014912310.1371/journal.pone.0114361 146.KinashiTOverview of integrin signaling in the immune"/>
</results>
